SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 1997
Commission File Number 1-13388
GUIDANT CORPORATION
(Exact name of Registrant as specified in its charter)
INDIANA 35-1931722
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
111 MONUMENT CIRCLE, 29TH FLOOR
INDIANAPOLIS, INDIANA 46204-5129
(Address of principal executive offices)
Registrant's telephone number, including area code: (317) 971-2000
Indicate by check mark whether the Registrant (1) has filed
all reports required to be filed by Section 13 or 15(d) of
the Securities Exchange Act of 1934 during the preceding 12
months (or for such shorter period that the Registrant was
required to file such reports), and (2) has been subject to
such filing requirements for the past 90 days.
Yes X No
------- ------
The number of shares of common stock outstanding as of April 22, 1997:
Class Number of Shares Outstanding
----- ----------------------------
Common 74,107,229
PART I
FINANCIAL INFORMATION
Item 1. Financial Statements
GUIDANT CORPORATION and Subsidiaries
Consolidated Statements of Income
(In millions, except per-share data)
(unaudited)
Three Months Ended
March 31,
------------------
1997 1996
----- -----
Net sales $265.5 $252.1
Cost of sales 66.0 77.0
---- ----
Gross profit 199.5 175.1
Research and development 42.3 36.0
Sales, marketing and administrative 84.2 77.3
---- ----
126.5 113.3
----- -----
Income from operations 73.0 61.8
Other income(expenses):
Interest, net (5.1) (7.3)
Royalties, net 4.5 0.1
Amortization of goodwill and other
intangible assets (4.1) (5.9)
Other, net (0.3) (1.6)
----- -----
(5.0) (14.7)
----- -----
Income before income taxes 68.0 47.1
Income taxes 24.8 18.6
---- ----
Net income $43.2 $ 28.5
===== =====
Earnings per share $0.60 $ 0.40
===== ======
Weighted average shares outstanding 72.17 71.99
Dividends paid per share $0.025 $0.025
====== ======
See notes to consolidated financial statements.
GUIDANT CORPORATION and Subsidiaries
Consolidated Balance Sheets
(In millions)
March 31, December 31,
1997 1996
----------- -----------
(unaudited)
ASSETS
Current Assets
Cash and cash equivalents $6.5 $1.5
Accounts receivable, net of allowances
of $7.0 (1997) and $7.3 (1996) 228.5 12.4
Other receivables 13.8 17.5
Inventories 103.2 102.8
Deferred income taxes 64.7 62.1
Prepaid expenses 22.9 22.6
---- ----
Total Current Assets 439.6 418.9
Other Assets
Goodwill, net of allowances
of $85.1 (1997) and $82.1 (1996) 191.8 197.3
Other intangible assets, net of allowances
of $9.8 (1997) and $8.8 (1996) 8.2 9.1
Investments 46.3 41.3
Sundry 16.4 16.3
Property and equipment 542.4 531.6
Less accumulated depreciation (219.5) (210.6)
------- -------
Property and equipment, net 322.9 321.0
----- -----
$1,025.2 $1,003.9
======== =======
See notes to consolidated financial statements.
GUIDANT CORPORATION and Subsidiaries
Consolidated Balance Sheets
(Dollars in millions)
March 31, December 31,
1997 1996
----------- ------------
(unaudited)
LIABILITIES AND SHAREHOLDERS' EQUITY
Current Liabilities
Accounts payable $26.1 $21.9
Employee compensation 37.0 77.5
Restructuring liabilities 9.1 8.8
Income taxes payable 37.1 2.6
Other liabilities 66.0 67.2
Current portion of long-term debt 115.8 130.0
----- -----
Total Current Liabilities 291.1 308.0
Noncurrent Liabilities
Long-term debt 233.5 233.5
Deferred income taxes 3.0 0.2
Other 12.1 14.0
----- ----
248.6 247.7
Commitments and contingencies -- --
Shareholders' Equity
Common stock-no par value;
Authorized shares: 250,000,000
Issued shares: 72,269,000 (1997) 192.5 192.5
72,154,000 (1996)
Additional paid-in capital 153.8 150.5
Retained earnings 203.4 162.0
Deferred cost, ESOP (48.8) (51.2)
Treasury stock, at cost:
Shares: 42,010 (1997)
66,763 (1996) (2.5) (3.3)
Unrealized gain on investments, net 11.2 9.4
Cumulative currency translation adjustments (24.1) (11.7)
------ ------
485.5 448.2
----- -----
$1,025.2 $1,003.9
======== ========
See notes to consolidated financial statements.
GUIDANT CORPORATION and Subsidiaries
Consolidated Statements of Cash Flows
(In millions)
Three Months Ended
March 31,
-------------------
1997 1996
---- ----
(unaudited)
Cash Provided by Operating Activities
Net income $ 43.2 $ 28.5
Adjustments to Reconcile Net Income to Cash
Provided by Operating Activities:
Depreciation 11.7 12.2
Amortization of intangible assets 4.1 5.9
Other noncash expenses, net 4.6 10.9
---- -----
63.6 57.5
Changes in Operating Assets and Liabilities:
Receivables, increase (19.6) (5.9)
Inventories, increase (6.3) (2.0)
Prepaid expenses, increase (0.9) (4.2)
Accounts payable and accrued expenses, decrease (24.3) (48.6)
Income taxes payable, increase 34.9 3.0
Other liabilities, (decrease) increase (1.4) 2.9
----- -----
Net Cash Provided by Operating Activities 46.0 2.7
Investing Activities:
Additions to property and equipment, net (16.2) (12.4)
Reductions of other assets, net (2.2) (3.3)
------ ------
Net Cash Used for Investing Activities (18.4) (15.7)
Financing Activities:
(Decrease) increase in borrowings (12.8) 16.3
Dividends (1.8) (1.8)
Purchase of common stock and other capital transactions (7.7) --
----- -----
Net Cash (Used for) Provided by Financing Activities (22.3) 14.5
Effect of Exchange Rate Changes on Cash (0.3) (2.4)
----- -----
Net Increase (Decrease) in Cash and Cash Equivalents 5.0 (0.9)
Cash and Cash Equivalents at Beginning of Period 1.5 3.4
----- -----
Cash and Cash Equivalents at End of Period $ 6.5 $ 2.5
====== ======
See notes to consolidated financial statements.
GUIDANT CORPORATION and Subsidiaries
Notes To Consolidated Financial Statements
(In millions)
(unaudited)
NOTE 1 - Basis of Presentation
The accompanying unaudited consolidated financial statements have
been prepared in accordance with generally accepted accounting
principles for interim financial information and with the
instructions to Form 10-Q and Article 10 of Regulation S-X.
Accordingly, they do not include all of the information and
footnotes necessary for a fair presentation of financial position,
results of operations and cash flow in conformity with generally
accepted accounting principles. In the opinion of management,
all adjustments (consisting of normal recurring accruals)
considered necessary for a fair presentation have been included.
For further information, refer to the consolidated financial
statements and footnotes thereto included in the Company's
Annual Report on Form 10-K for the year ended December 31, 1996.
NOTE 2 - Inventories
Inventories consisted of the following:
March 31, December 31,
1997 1996
-------- ------------
Finished products $ 48.1 $ 48.4
Work in process 30.1 28.8
Raw materials and supplies 25.0 25.6
----- -----
$103.2 $102.8
====== ======
NOTE 3 - Contingencies
The Company is a party to various legal actions which have
occurred in the normal course of business. In May 1995,
Intermedics, Inc., a division of Sulzermedica USA, Inc., filed
suit against Guidant alleging patent infringement related to
certain Guidant defibrillator and pacemaker models. Intermedics
is seeking injunctive and monetary relief of an unspecified amount.
The Company has also been named as a defendant, along with
Schneider (USA), Inc., and Schneider (Europe), AG, wholly owned
subsidiaries of Pfizer, Inc., in an action brought in 1995 by
Boston Scientific Corporation and its subsidiary, SCIMED Life
Systems, Inc. The lawsuit alleges violation of federal and state
antitrust laws, as well as state unfair competition and abuse of
process laws. Boston Scientific and SCIMED allege that the
violations are based on the misuse of the United States patent
laws as a result of agreements concerning certain rapid exchange
catheter patents. The lawsuit seeks injunctive relief,
unspecified monetary damages, and a declaration that certain
patents are unenforceable.
GUIDANT CORPORATION and Subsidiaries
Notes To Consolidated Financial Statements
(In millions)
(unaudited)
NOTE 3 - Contingencies (continued)
On May 3, 1996, Pacesetter, Inc., filed suit against the Company
in the United States District Court for the District of Delaware.
The lawsuit was subsequently transferred to the United States
District Court for Minnesota. The complaint, as subsequently
amended, alleges infringement of certain patents related to the
Company's VIGOR pacemaker/programmer and the VENTAK MINI and
seeks injunctive relief, unspecified monetary damages, and an
award of attorneys' fees.
The Company is a party to certain other legal actions arising in
the ordinary course of its business. While it is not possible to
predict or determine the outcome of the legal actions brought
against it, the Company believes the costs associated with all of
these actions will not have a material adverse effect on its
consolidated financial position or liquidity, but could possibly
be material to the consolidated results of operations in any one
accounting period.
Further, product liability claims may be asserted in the future
relative to events currently unknown to management. Management
believes that the Company's risk-management practices, including
insurance coverage, are reasonably adequate to protect against
potential product liability losses.
NOTE 4 - Earnings Per Share
Earnings per share of common stock has been computed by dividing
net income by the weighted average common share outstanding
during the period. In February 1997, the Financial Accounting
Standards Board issued Statement No. 128, Earnings per Share.
Under Statement No. 128, which is required to be adopted on
December 31, 1997, the disclosure of fully diluted earnings per
share will be mandatory in the financial statements. At that
time, the Company will be required to change the method currently
used to compute earnings per share and to restate all prior
periods. The impact of the new requirements for calculating
earnings per share is not material for the three months ended
March 31, 1997 and March 31, 1996.
Item 2. Management's Discussion and Analysis of Results of Operations
and Financial Condition
Guidant Corporation (Guidant or the Company), an Indiana
corporation, is a multinational company that designs, develops,
manufactures, and markets a broad range of products for use in:
(i) cardiac rhythm management (CRM), (ii) vascular intervention (VI),
and (iii) other forms of minimally invasive systems (MIS). In CRM,
the Company is a worldwide leader in automatic implantable cardioverter
defibrillator (AICD) systems. The Company also designs,
manufactures, and markets a full line of implantable pacemaker
systems used in the treatment of slow or irregular heartbeats.
In VI, the Company is a worldwide leader in minimally invasive
procedures used for opening blocked coronary arteries. In
addition, the Company develops, manufactures, and markets products
for use in MIS procedures with products for access, vision,
dissection, retraction, and fixation, focusing on laparoscopic
market opportunities in both general and cardiovascular surgeries.
The following tables are summaries of the Company's net sales and
major costs and expenses:
Three Months Ended March 31,
----------------------------
1997 1996
---- ----
(Dollars in millions)
Cardiac Rhythm Management $149.0 $133.8
Vascular Intervention 100.8 106.9
Minimally Invasive Systems 15.7 11.4
----- -----
Total net sales 265.5 252.1
Cost of sales 66.0 77.0
----- -----
Gross profit 199.5 175.1
Research and development 42.3 36.0
Sales, marketing, and
administrative 84.2 77.3
----- ----
126.5 113.3
----- -----
Income from operations $73.0 $61.8
===== =====
As a Percent of Net Sales
-------------------------
Three Months Ended March 31,
----------------------------
1997 1996
---- ----
Cardiac Rhythm Management 56.1% 53.1%
Vascular Intervention 38.0 42.4
Minimally Invasive Systems 5.9 4.5
---- ----
Total net sales 100.0% 100.0%
====== ======
Cost of sales 24.9 30.5
---- ----
Gross profit 75.1 69.5
Research and development 15.9 14.3
Sales, marketing, and
administrative 31.7 30.7
---- ----
47.6 45.0
---- ----
Income from operations 27.5% 24.5%
===== =====
Operating Results -- Three Months Ended March 31, 1997
The Company had worldwide net sales of $265.5 million for the
three months ended March 31, 1997, reflecting an increase of
$13.4 million or 5% over the same period in 1996. Growth in unit
volume of 17% was offset by net sales price decreases, including
changes in product mix, and unfavorable fluctuations in foreign
currency exchange rates of 9% and 3%, respectively.
Net sales of CRM products for the three months ended March 31,
1997 were $149.0 million, an increase of $15.2 million or 11.4%
over the same period in 1996. This growth was led by strong
worldwide sales of the VENTAK MINI II advanced, tiered-therapy
automatic implantable cardioverter-defibrillators (AICDs), released
in the United States in July 1996; the VENTAK MINI HC, released
in the United States in May 1996; and the VENTAK MINI, released
in the United States in January 1996. The technologically advanced
VENTAK MINI II, one of the world's smallest full-featured AICDs,
and the VENTAK MINI HC, incorporate the Company's exclusive TRIAD
defibrillation energy delivery system which is designed to simplify the
device implant procedure and reduce the energy needed for defibrillation.
The Company's adaptive-rate pacemaker products also contributed to
sales growth during the period led by the VIGOR DR and VIGOR SR.
Net sales of vascular intervention products for the three months
ended March 31, 1997, were $100.8 million, a decrease of $6.1
million or 5.7% from the same period in 1996. The Company
experienced unit sales growth in certain angioplasty systems
including: (i) the ACS RX MULTI-LINK Coronary Stent System (rapid
exchange stent delivery), and the ACS OTW MULTI-LINK Coronary
Stent System (over-the-wire stent delivery) launched in Europe
and other international markets in April 1996 and November 1995,
respectively; (ii) rapid exchange dilatation catheters, primarily
the ACS RX COMET, released to international markets in June 1996
and to the United States market in November 1996 and its high-
pressure counterpart the ACS RX COMET VP which has recently been
cleared by the Food and Drug Administration for marketing in the
United States; and (iii) the ACS HI-TORQUE IRON MAN Guide Wire
which was released to the United States market in February 1997.
The ACS HI-TORQUE IRON MAN Guide Wire combines a flexible core
with an atraumatic, soft tip, allowing for easy maneuverability
and enabling physicians to cross difficult-to-reach lesions, and
is specifically designed for utilization in the placement of
coronary stents. This sales growth was offset by sales declines
in perfusion, OTW, and atherectomy catheters, and lower net
average selling prices of most dilatation catheters in the United
States and Europe. These lower net average selling prices of
dilatation catheters include the impact of product mix changes
due to the sales growth in rapid exchange catheters. The Company
believes that, in addition to this shift in product mix, net
average selling prices in the market may continue to decline.
Net sales of MIS products for the three months ended March 31,
1997, were $15.7 million, an increase of $4.3 million or 37.7%
over the comparable period in 1996. MIS sales growth was
experienced both in the United States and international markets
as the Company continued to expand the marketing of its
innovative laparoscopic technologies. Sales growth was driven by
the ORIGIN TACKER endoscopic fixation device; custom procedural
kits which incorporate this device along with other MIS products;
and, to some degree, the VASOVIEW Balloon Dissection system,
market released in September 1996.
The Company experienced sales growth both in the United States
and international markets during the first quarter of 1997. Net
sales in the United States increased 1.4% to $162.9 million and
international net sales increased 12.3% to $102.6 million for the
first quarter of 1997 compared to the first quarter of 1996.
United States net sales growth was primarily due to CRM sales of
the VENTAK MINI II, VENTAK MINI, VENTAK MINI HC, VIGOR DR, and
VIGOR SR. International net sales growth was primarily driven by
European sales of the ACS RX MULTI-LINK Coronary Stent System,
VENTAK MINI II, and VENTAK MINI HC. Sales of the ACS RX COMET in
Europe and Japan also contributed to the international sales
growth. The unfavorable foreign currency exchange rate impact,
due to the strengthening United States dollar, reduced net sales
for the three months ended March 31, 1997 by $8.5 million
compared to the same period in 1996. This negative impact on
gross profit was partially offset by foreign exchange gains,
which were recorded in cost of sales, relating to the Company's
hedging activities established for this purpose.
Cost of sales decreased 14.3% to $66.0 million for the three
months ended March 31, 1997. This reduction in cost of sales was
due to: (i) a significant reduction in inventory obsolescence
charges which were $7.2 million in the first quarter of 1996,
(ii) gains of $3.5 million realized on the foreign exchange
hedges referred to above, (iii) increased manufacturing volume,
and (iv) enhanced manufacturing efficiencies in all business units.
The Company continued its commitment to achieving long-term
growth by investing significant resources in research and
development. Research and development expenses increased $6.3
million or 17.5% in the first quarter of 1997 compared to the
same period in 1996. Increased research and development spending
during this period resulted primarily from new product development
costs such as the clinical evaluation of implantable device
systems for the treatment of congestive heart failure and the
development of future generations of AICD and pacemaker products.
Sales, marketing and administrative expenses grew $6.9 million or
8.9% for the first quarter of 1997 compared to the same period in
1996. Variable CRM selling expenses associated with the United
States market releases of the VENTAK MINI family of AICDs were
among the drivers of the increased sales and marketing expenses
during the period. Increased legal expenses and the timing of
certain employee benefits expenses also contributed to the increase
in sales, marketing, and administrative expenses during the period.
During the period, the Company attained near record levels of
operating income for a fiscal quarter. Income from operations of
$73.0 million represented 27.5% of net sales during the first
quarter of 1997. Income from operations was 24.5% of net sales
during the same period in 1996. Sales growth combined with
reduced manufacturing expenses resulted in an increase in income
from operations of 18.1% during the three months ended March 31,
1997, compared to the same period last year.
For the three months ended March 31, 1997, the Company had net
other expenses of $5.0 million as compared to $14.7 million
during the same period in 1996. The decrease in net other
expenses was primarily due to: (i) lower interest expenses due
to the decline in outstanding borrowings and lower interest
rates; (ii) increased net royalties received on certain vascular
intervention technology patents; and (iii) reduced amortization
expense resulting from lower intangible assets following the
impairment charges taken by the Company against its atherectomy-
related goodwill and other intangible assets in the second
quarter of 1996.
The Company's effective income tax rate for the three months
ended March 31, 1997 was 36.5%, compared to 39.5% during
the comparable period in 1996. The decline in this rate was
primarily due to reduced state income taxes, lower income taxes
in certain international locations, and the reduced impact of
nondeductible expenses.
Net income for the three months ended March 31, 1997, was $43.2
million, an increase of $14.7 million or 51.6% compared to the
same period in 1996. Earnings per share were $0.60 for the three
months ended March 31, 1997, compared to $0.40 for the comparable
period in 1996. This increase in net income and earnings per
share was due to operating income growth of 18.1%, reduced net
other expenses, and a lower effective income tax rate.
Liquidity and Financial Condition
The Company generated cash flows which were more than sufficient
to fund operations. For the three months ended March 31, 1997,
cash provided by operating activities was $46.0 million compared
to $2.7 million for the same period in 1996. This increase in
cash provided by operating activities was primarily due to net
income growth of over 50% during the period and the final income
tax payments under a tax-sharing agreement with Lilly in 1996.
Working capital was $148.5 million at March 31, 1997, a $37.6
million increase from the prior year end level. This increase
was primarily due to payments of performance-based compensation
arrangements and the resultant reduction in employee compensation
accruals, payments on borrowings, and increased accounts
receivable resulting from sales growth during the period. The
current ratio at March 31, 1997 was 1.5:1 compared to 1.4:1 at
December 31, 1996. The Company expects to generate sufficient
cash to fund future working capital needs.
Net cash used for investing activities totaled $18.4 million for
the three months ended March 31, 1997, compared to $15.7 million
for the same period in 1996. The most significant use of cash
for investing activities related to net additions of property and
equipment of $16.2 million. Net additions of property and
equipment for the same period in the prior year were $12.4 million.
Net cash used for financing activities totaled $22.3 million for
the three months ended March 31, 1997. Reduction of its
borrowings by $12.8 million was the Company's most significant
use of cash for financing activities. For the three months ended
March 31, 1996, net cash provided by financing activities was
$14.5 million primarily due to increased net borrowings of $16.3
million to fund first quarter 1996 tax payments and performance-
based bonus compensation.
At March 31, 1997, the Company had outstanding borrowings of
$349.3 through the issuance of commercial paper and bank
borrowings at a weighted average interest rate of 5.36%. The
commercial paper borrowings are supported by a credit facility
aggregating $600.0 million that permits borrowings through
January 8, 2001. This credit facility, under which there are
currently no outstanding borrowings, carries a variable market
rate of interest. The Company expects that a minimum of
approximately $233.5 million of borrowings will remain outstanding
through the next twelve months and, accordingly, has classified
this portion of borrowings as long-term at March 31, 1997.
The Company expects its cash from operations to be adequate to
meet its obligations to make interest payments on its debt and
other anticipated cash needs including planned capital expenditures
which are expected to be approximately $70.0 million in 1997.
The Company has recognized net deferred tax assets aggregating
$61.7 million at March 31, 1997, and $61.9 million at December
31, 1996. The assets relate principally to the establishment of
inventory and product related reserves, the acquisition of
certain intangible assets, and charges associated with the 1993
restructuring. In view of the consistent profitability of its
past operations, the Company believes that all these assets will
be substantially recovered and that no significant additional
valuation allowances are necessary.
PART II
OTHER INFORMATION
Item 6. Exhibits and Reports on Form 8-K
(a) Exhibits. The following documents are filed as exhibits
to this report.
Exhibit 11.1. Statement Regarding Computation
of Per-Share Earnings on Primary
and Fully Diluted Bases.
Exhibit 27.1. Financial Data Schedule.
(b) Reports on Form 8-K. During the quarter for which this
Report on Form 10-Q is filed, the Registrant filed no Report
on Form 8-K.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the Registrant has duly caused this Report to be signed on
its behalf by the undersigned thereunto duly authorized.
GUIDANT CORPORATION
(Registrant)
Date: May 5, 1997 s/Keith E. Brauer
--------------------------------
Keith E. Brauer
Vice President, Finance and
Chief Financial Officer
Date: May 5, 1997 s/ Roger Marchetti
--------------------------------
Roger Marchetti
Corporate Controller and
Chief Accounting Officer
Exhibit List
11.1 Statement Regarding Computation of Per-Share
Earnings on Primary and Fully Diluted Bases
27.1 Financial Data Schedule
GUIDANT CORPORATION and Subsidiaries
EXHIBIT 11.1
Statement Regarding Computation of Per-Share Earnings
on Primary and Fully Diluted Bases
(In millions, except per-share data)
Three Months Ended March 31,
1997 1996
---- ----
Primary:
Net income $43.2 $28.5
Weighted average common shares outstanding 72.17 71.99
Incremental shares:
Stock plans 1.48 0.93
----- -----
Adjusted average common shares outstanding 73.65 72.92
Primary earnings per share $0.59 $0.39
===== =====
Fully Diluted:
Net income $43.2 $28.5
Weighted average common shares outstanding 72.17 71.99
Incremental shares:
Stock plans 1.55 1.05
----- -----
Adjusted average common shares outstanding 73.72 73.04
Fully diluted earnings per share $0.59 $0.39
===== =====
Common stock equivalents are not materially dilutive and, accordingly, have
not been considered in the computation of per-share earnings which appears
on the Consolidated Statements of Income.
<TABLE> <S> <C>
<ARTICLE> 5
<MULTIPLIER> 1,000
<S> <C>
<PERIOD-TYPE> 3-MOS
<FISCAL-YEAR-END> DEC-31-1997
<PERIOD-START> JAN-01-1997
<PERIOD-END> MAR-31-1997
<CASH> 6,500
<SECURITIES> 0<F1>
<RECEIVABLES> 235,500
<ALLOWANCES> 7,000
<INVENTORY> 103,200
<CURRENT-ASSETS> 439,600
<PP&E> 542,400
<DEPRECIATION> 219,500
<TOTAL-ASSETS> 1,025,200
<CURRENT-LIABILITIES> 291,100
<BONDS> 233,500
0<F1>
0<F1>
<COMMON> 192,500
<OTHER-SE> 293,000
<TOTAL-LIABILITY-AND-EQUITY> 1,025,200
<SALES> 265,500
<TOTAL-REVENUES> 265,500
<CGS> 66,000
<TOTAL-COSTS> 66,000
<OTHER-EXPENSES> 42,300
<LOSS-PROVISION> 0<F1>
<INTEREST-EXPENSE> 5,100
<INCOME-PRETAX> 68,000
<INCOME-TAX> 24,800
<INCOME-CONTINUING> 0<F1>
<DISCONTINUED> 0<F1>
<EXTRAORDINARY> 0<F1>
<CHANGES> 0<F1>
<NET-INCOME> 43,200
<EPS-PRIMARY> .59
<EPS-DILUTED> .59
<FN>
<F1>Does not apply.
</FN>
</TABLE>
